Other Clinical Trial - The Staircase Phenomenon Implications on

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The staircase phenomenon could have repercussions on the onset and recovery time following administration of a neuromuscular blocking agent. The investigators aim to assess the magnitude of the staircase phenomenon and its impact on various aspects of neuromuscular blockade with a randomized controlled double blind trial.

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT05716282` - Estimation of Neuromuscular Recovery - a Validation Study
	Not yet recruiting	`NCT05228223` - Comparison of Sugammadex and Sugammadex-neostigmine Combination in the Antagonism of Moderate Neuromuscular Block	N/A

NCT number	NCT03146767
Study type	Interventional
Source	Hospital Universitario La Fe
Contact
Status	Completed
Phase	N/A
Start date	February 2013
Completion date	March 2014

The Staircase Phenomenon Implications on Neuromuscular Block Monitoring

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms